The KCNH7 antibody targets the potassium voltage-gated channel subfamily H member 7 (KCNH7), a protein encoded by the KCNH7 gene. This channel belongs to the ether-à-go-go (EAG) family of voltage-gated potassium channels, which regulate neuronal excitability and repolarization of action potentials. KCNH7 is primarily expressed in the central nervous system, particularly in the hippocampus, cortex, and cerebellum, where it contributes to modulating electrical signaling and synaptic plasticity. Its function is linked to delayed rectifier potassium currents, influencing neuronal firing patterns and network oscillations.
Antibodies against KCNH7 are essential tools for studying its expression, localization, and physiological roles. They are commonly used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect KCNH7 in tissue or cell lysates. Research involving KCNH7 antibodies has explored its potential involvement in neurological disorders, including epilepsy, cognitive deficits, and psychiatric conditions, as channel dysfunction may disrupt neural circuit balance. Additionally, studies suggest KCNH7 polymorphisms could associate with neurodevelopmental disorders, though mechanisms remain under investigation. Validated antibodies with high specificity are critical to avoid cross-reactivity with homologous channels like KCNH5 or KCNH6. Recent work also highlights KCNH7's role in non-neuronal tissues, such as endocrine cells, broadening its biomedical relevance. Proper antibody validation via knockout controls or siRNA knockdown remains crucial for reliable data interpretation.